All News

ACHILLES study: Only 56% of pts w/ clinical enthesitis had MRI+ heel enthesitis. MRI screening: HLAB27+ pts likely to be in MRI+ grp. @RheumNow #ACR20 Abstr#0447 #ACRbest https://t.co/m2cjDzYfyg
sheila RHEUMarampa ( View Tweet)
More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Evidence for Dr. Strand to use in #ACR20 Great Debate that VTE may be safe TNF alternative @RheumNow. https://t.co/hByttIxiuX
Eric Dein ejdein1 ( View Tweet)
“Immunology is the cornerstone of medicine and we are the experts.” #ACR20 president, Dr. Ellen Gravallese @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Sustained DMARD-free remission (SFDR) seen in ACPA- RA pts; DAS levels at 4mos. predictive for SFDR. ACPA+ pts no relation w/ SFDR & DAS course @RheumNow #ACR20 Abstr#479 #ACRbest https://t.co/kko4tO7s1Y
sheila RHEUMarampa ( View Tweet)
Small study showed poor to fair agreement of PE and US findings of hands in PsA. Do you use US in your clinic for diagnostics? #ABS0314 @RheumNow #ACR20 https://t.co/6oQG4SB1d3 https://t.co/SQK7uhX02T

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
JAKs are no longer new, Winthrop et al presents 8.4 year BARI data in Abst#0202 at #ACR20. VTE risk stable over time, again shows reason to vaccinate patients for zoster before starting. @RheumNow https://t.co/OSIvHl2f7Y
Eric Dein ejdein1 ( View Tweet)
Beautiful poster and fascinating research from @chriswincup et al showing immune cellular iron deficiency in patients with #SLE. Time to add iron supplementation as part of standard #lupus therapy? https://t.co/Uf81KXbSM0 Abs#0294 #ACR20 @RheumNow https://t.co/z5SUjWFkdD

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Abst#0181 out of Korea shows MTX use does not increase prevalence of hepatic steatosis. Encouraging data, though retrospective study may underpin provider bias in riskier patients. #ACR20 @RheumNow. https://t.co/HeR5hroYUh
Eric Dein ejdein1 ( View Tweet)
ANA antibodies in longitudinal #SLE cohort: - 759 patients - 84.8% remained ANA+ve during 5yr followup period - Pts w/ at least one -ve ANA in first 5yrs had milder disease (lower SLEDAI-2K, less steroid, fewer autoantibodies) Abs#0251 #ACR20 @RheumNow https://t.co/U7JbNpJA3w

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Large data from Japanese Ninja database in abst#0183 shows incidence of malignancies in Japanese RA patients similar to Japanese gen pop. Comparable in patients exposed and unexposed to biologics/JAKs. #ACR20 @RheumNow

Eric Dein ejdein1 ( View Tweet)

15 % of Relapsing Polychondritis meet diagnosis for MAGIC syndrome (Mouth and genital ulcers with inflamed cartilage) - overlap of RP and Behcet's Abst#0425 #ACR20 #ACRbest @RheumNow https://t.co/qaHWwOOL7Q
Bella Mehta bella_mehta ( View Tweet)
Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest

Robert B Chao, MD doctorRBC ( View Tweet)

PMR takes fit patients, and drags them down. In this @HSpecialSurgery cohort, PMR patients were more frail: worse physical function, fatigue, and pain - despite a low comorbidity burden. We need to understand the burden of PMR better. IL-6? @SattuiSEMD #ACR20 ABST0422 @RheumNow https://t.co/j6HLNA7ANv
David Liew drdavidliew ( View Tweet)
Dr. Weinblatt dodges the question which TNFi prefers after MTX-IR. Which one do you choose? #ACR20 #GreatDebate @RheumNow

k dao KDAO2011 ( View Tweet)

Dr.Gonzalez-Mazon describes surrogate markers assoc'd w #atherosclerosis in #axSpA: BASFI, BASMI, IBD, ESR, CRP, prednisone and DMARDs use. @RheumNow #ACR20 abst#0448 https://t.co/g27qA4qpPL
sheila RHEUMarampa ( View Tweet)
Abst#0135 at #ACR20 illustrates the drivers of patient satisfaction per a survey of 374 U.S. pts. The biggest obstacles to managing RA are pain (80%), fatigue (72%), & depression/anxiety (51%), but only 51% of pts feel that these are addressed. @RheumNow https://t.co/I2ac2T2TOA
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
The GRA now have >17,000 pts registered! Watch the video link @rheumnow or YouTube: https://t.co/tdp5q7tAPK Please visit the GRA booth @rheum_cat @JYazdanyMD @philipcrobinson @rheum_covid #ACR20 https://t.co/UObvGO3n9Q

Links:

k dao KDAO2011 ( View Tweet)

Agreed- hence the debate is more about patient preference and we need to equip patients with enough information to make correct choices for themselves! @ACRheum @RheumNow #ACR20 https://t.co/zp8HX0YPBV

Links:

alexa meara lexmeara ( View Tweet)

Where one lives matters! Especially during the #COVID19 "flares" - Geographical variations in risk perception and medication management by rheumatologists vary by #COVID19 case burden in the community. Check our abst#0005 #ACR20 @RheumNow

Bella Mehta bella_mehta ( View Tweet)

What's your initial biologic of choice when escalating therapy for PsA patients non-responsive to csDMARDs? @RheumNow #ACR20

sheila RHEUMarampa ( View Tweet)

×